Page 38 - Haematologica March 2020

P.M. Mannucci et al.
Willebrand's disease. N Engl J Med. 2016;
375(21):2067-2080.
7. Sadler JE, Mannucci PM, Berntorp E. Impact,
diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84(2):160- 174.
8. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the preva- lence of von Willebrand's disease. Blood. 1987;69(2):454-459.
9. Mannucci PM. New therapies for von Willebrand disease. Blood Adv. 2019;3(21): 3481-3487.
10. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vaso- pressin: a new pharmacological approach to the management of haemophilia and von Willebrands’ diseases. Lancet. 1977 23;1 (8017):869-872
11. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treat- ments, and its complications. Lancet. 2016;388(10040):187-197.
12. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9(4):418-435.
13. Rocino A, Franchini M, Coppola A. Treatment and prevention of bleeds in haemophilia patients with inhibitors to fac- tor VIII/IX. J Clin Med. 2017;6(4): E46.
14. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007;13 (Suppl 1):1-22.
15. Hay CR, DiMichele DM; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose com- parison. Blood. 2012;119(6):1335-1344.
16. Plug I, Van Der Bom JG, Peters M, et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost. 2006;4(3): 510-516.
17. Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110(3):815-825.
18. Tagliaferri A, Rivolta GF, Iorio A, et al. Mortality and causes of death in Italian per- sons with haemophilia, 1990-2007. Haemophilia. 2010;16(3):437-446.
19. Carcao MD, Aledort L. Prophylactic factor replacement in hemophilia. Blood Rev. 2004;18(2):101-113.
20. Bolton-Maggs PH. Optimal haemophilia care versus the reality. Br J Haematol. 2006; 132(6):671-682.
21. Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med. 2013;4:49-56.
22. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treat- ment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357 (6):535-544.
23. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM; ESPRIT Study Group. A randomized clinical trial of pro- phylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011;9 (4):700-710.
24. Chen SL. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care. 2016;22(5 Suppl):s126-133.
25. Dumont JA, Liu T, Low SC, et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and
dogs. Blood. 2012;119(13):3024-3030.
26. Schulte S. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. Thromb Res
2013;131 (Suppl. 2):s2-s6
27. Ivens IA, Baumann A, McDonald TA, et al.
PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia. 2013;19(1):11-20.
28. Swierczewska M, Lee KC, Lee S. What is the future of PEGylated therapies? Expert Opin Emerg Drugs. 2015;20(4):531-536.
29. Roopenian DC, Akilesh S. FcRn: the neona- tal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715-725.
30. Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombi- nant factor VIII Fc fusion protein in hemo- philia A patients. Blood. 2012;119(13):3031- 3037.
31. Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 2012;119(3):666-672.
32. Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123(3):317-325.
33. Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treat- ment of severe hemophilia A. Blood. 2015;126(9):1078-1085.
34. Mullins ES, Stasyshyn O, Alvarez-Román MT, et al. Extended half-life pegylated, full- length recombinant factor VIII for prophy- laxis in children with severe haemophilia A. Haemophilia. 2017;23(2):238-246.
35. Reding MT, Ng HJ, Poulsen LH, et al. Safety and efficacy of BAY 94-9027, a prolonged- half-life factor VIII. J Thromb Haemost. 2017;15(3):411-419.
36. Santagostino E, Lalezari S, Reding MT, et al. Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial. Thromb Res. 2019;183:13-19.
37. Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. Thromb Haemost. 2017;117(2):252-261.
38. Meunier S, Alamelu J, Ehrenforth S, et al. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Thromb Haemost. 2017;117(9):1705- 1713.
39. Gruppo R, López-Fernández MF, Wynn TT, Engl W, Sharkhawy M, Tangada S. Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial. Haemophilia. 2019;25(5):773-781.
40. Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagula- tion factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012;120(12): 2405-2411.
41. Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus 2019;17:479-486
42. Mancuso ME, Santagostino E. Outcome of clinical trials with new extended half-life
FVIII/IX concentrates. J Clin Med. 2017;6:
E39.
43. Baumann A, Piel I, Hucke F, Sandmann S,
Hetzel T, Schwarz T. Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94- 9027 in rats and its value for human predic- tion. Eur J Pharm Sci. 2019 Mar 15;130:11-20.
44. Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood. 2003;102(7): 2358-2363.
45. Kitazawa T, Igawa T, Sampei Z, et al. A bis- pecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10): 1570-1574.
46. Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific anti- body, in healthy subjects. Blood. 2016;127(13):1633-1641.
47. Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispe- cific antibody in hemophilia A. N Engl J Med. 2016;374(21):2044-2053.
48. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377 (9):809-818.
49. Young G, Liesner R, Sidonio R, et al. Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia with Inhibitors: Results from the HAVEN 2 Study. Paper presented at: American Society of Hematology Annual Meeting; December 1 4, 2018; San Diego
50. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811-822.
51. Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizum- ab prophylaxis given every 4 weeks in peo- ple with haemophilia A (HAVEN 4): a mul- ticentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6):e295- e305.
52. Samuelson Bannow B, Recht M, Négrier C, et al. Factor VIII: long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Rev. 2019;35:43- 50.
53. Fatalities in emicizumab-kxwh clinical trials, expanded access,compassionate use, and the postmarketing setting. South San Francisco, CA: Genentech, 2018 (https://www.emicizumabinfo.com/con- tent/dam/gene/emicizumabinfo/hcp/pdfs/fa talities.pdf).
54. FDA adverse events reporting system (FAERS) public dashboard: FAERS cases 14455349 and 16262656. Rockville, MD: Food and Drug Administration (https://fis.fda.gov/sense/app/d10be6bb- 494e-4cd2-82e4-0135608ddc13/sheet/ 33a0f68e-45c-48e2-bc81-8141c6aaf772/ state/ analysis).
55. Aledort LM. Deaths associated with emi- cizumab in patients with hemophilia A. N Engl J Med. 2019;381(19):1878-1879.
56. Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volun- teers and patients with hemophilia: a ran- domized first human dose trial. J Thromb Haemost. 2015;13(5):743-754.
57. Eichler H, Angchaisuksiri P, Kavakli K, et al. A randomized trial of safety, pharmacoki-
552
haematologica | 2020; 105(3)